Drugs / RS-C1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06669429 | Sep 2024 → Jun 2025 overdue | hyperlipidemia | Peking University First Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RS-C1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06669429 ↗ |
| Route | Oral | “Subjects will receive RS-C1001 tablets orally as a single ascending dose” NCT06669429 ↗ |